Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VENOTREAT: Venoactive Drugs in Pelvic Venous Disorders
NCT06584799Phase 3Recruiting
- Sponsor
- Pirogov Russian National Research Medical University
- Start
- Dec 2024
- Primary completion
- Jan 2025
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of micronized purified flavonoid fraction and diosmin in Pelvic venous disorder (PeVD) (3 arms), sponsored by Pirogov Russian National Research Medical University. Primary endpoint: Severity of Chronic Pelvic Pain at 8 weeks. Started Dec 2024; status: recruiting.
02
Drugs
micronized purified flavonoid fractiondiosmin
03
Conditions
Pelvic venous disorder (PeVD)
Beyond the preview
Go deeper on NCT06584799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06584799.